Teva Statement Following New York Jury Ruling in Opioids Trial
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announces plans to appeal a recent unfavorable legal ruling regarding opioid prescriptions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
In NY, the plaintiffs presented no evidence of medically unnecessary prescriptions, suspicious or diverted orders, no evidence of oversupply by the defendants – or any indication of what volumes were appropriate – and no causal relationship between Teva’s conduct including its marketing and any harm to the public in the state.
Prior to deliberation, Teva sought a mistrial based on, among other issues, the state’s misrepresentation of the amount of opioids sold by Teva in NY by more than 500 times.
Teva continues to focus on increasing access to essential medicines to patients, including opioid medications for approved indications. Most importantly, the Company continues to pursue a national settlement in the best interest of patients.
As recently as last month, a court in
Additionally, last month the
View source version on businesswire.com: https://www.businesswire.com/news/home/20211230005283/en/
IR Contacts
(267) 468-4475
972 (3) 914-8262
PR Contacts
(973) 658-0237
(973) 264 7378
Source: